Literature DB >> 12906716

Influence of the TNF-alpha and TNF-beta polymorphisms upon infectious risk and outcome in surgical intensive care patients.

Jacqueline E Calvano1, John Y Um, Doreen M Agnese, Sae J Hahm, Ashwini Kumar, Susette M Coyle, Steve E Calvano, Stephen F Lowry.   

Abstract

BACKGROUND: Tumor necrosis factor-alpha (TNF-alpha) is a well-documented central inflammatory mediator in sepsis. Specific polymorphisms of the TNF-alpha and TNF-beta genes (TNF2 and LTA + 250, respectively) have been suggested to correlate with higher mortality in septic shock. This study sought to determine whether these polymorphisms of the TNF-alpha and -beta genes are associated with an increased risk of infection in an at-risk surgical intensive care population.
MATERIALS AND METHODS: Forty-four consecutive patients with systemic inflammatory response syndrome were enrolled prospectively in the study. Genomic DNA was isolated from whole blood samples using standard phenol/chloroform extraction techniques. Specific fragments including the polymorphic sites of each gene were amplified by polymerase chain reaction, and restriction enzyme digestions were performed. Genotypes were determined by gel electrophoresis and confirmed by direct sequencing.
RESULTS: Eighty-six percent of the patients were TNF1 homozygotes (G:G at -308 of the TNF-alpha promoter region), whereas 9% of the patients were homozygous for TNF2 (A:A). There was no difference in the incidence of sepsis, septic shock, or mortality between patients bearing the various alleles. Only 13.6% of the patients exhibited the G:G alleles for TNF-beta, whereas the homozygous A:A was present in 45.4% of the patients.
CONCLUSION: The presence of the A allele at these polymorphic sites did not predispose critically ill surgical patients to either infection or septic shock.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12906716     DOI: 10.1089/109629603766956951

Source DB:  PubMed          Journal:  Surg Infect (Larchmt)        ISSN: 1096-2964            Impact factor:   2.150


  7 in total

1.  Ethical considerations in the collection of genetic data from critically ill patients: what do published studies reveal about potential directions for empirical ethics research?

Authors:  B D Freeman; C R Kennedy; H L Frankel; B Clarridge; D Bolcic-Jankovic; E Iverson; E Shehane; A Celious; B A Zehnbauer; T G Buchman
Journal:  Pharmacogenomics J       Date:  2009-12-08       Impact factor: 3.550

Review 2.  Cytokine storm and sepsis disease pathogenesis.

Authors:  Benjamin G Chousterman; Filip K Swirski; Georg F Weber
Journal:  Semin Immunopathol       Date:  2017-05-29       Impact factor: 9.623

3.  Heterogeneity in lipopolysaccharide responsiveness of endothelial cells identified by gene expression profiling: role of transcription factors.

Authors:  G C Beck; N Rafat; P Brinkkoetter; C Hanusch; J Schulte; M Haak; K van Ackern; F J van der Woude; B A Yard
Journal:  Clin Exp Immunol       Date:  2006-03       Impact factor: 4.330

4.  Genetic variation in the TNF gene is associated with susceptibility to severe sepsis, but not with mortality.

Authors:  Zhenju Song; Yuanlin Song; Jun Yin; Yao Shen; Chenling Yao; Zhan Sun; Jinjun Jiang; Duming Zhu; Yong Zhang; Qinjun Shen; Lei Gao; Chaoyang Tong; Chunxue Bai
Journal:  PLoS One       Date:  2012-09-27       Impact factor: 3.240

5.  Association between the Lymphotoxin-α A252g Gene Polymorphism and the Risk of Sepsis and Mortality: A Meta-Analysis.

Authors:  Shujin Guo; Qiunan Zuo; Xiaohui Li; Ye He; Yutian Zhou
Journal:  Biomed Res Int       Date:  2020-08-20       Impact factor: 3.411

6.  The effects of tumor necrosis factor-α (TNF-α) rs1800629 and rs361525 polymorphisms on sepsis risk.

Authors:  Yixin Zhang; Xiaoteng Cui; Li Ning; Dianjun Wei
Journal:  Oncotarget       Date:  2017-11-30

7.  Tumor necrosis factor-α -308 G/A polymorphism and risk of sepsis, septic shock, and mortality: an updated meta-analysis.

Authors:  Hao Wang; Shujin Guo; Chun Wan; Ting Yang; Ni Zeng; Yanqiu Wu; Lei Chen; Yongchun Shen; Fuqiang Wen
Journal:  Oncotarget       Date:  2017-09-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.